Fulcrum Therapeutics (NASDAQ:FULC) Rating Reiterated by Svb Leerink

Share on StockTwits

Fulcrum Therapeutics (NASDAQ:FULC)‘s stock had its “outperform” rating reissued by investment analysts at Svb Leerink in a report issued on Monday, Zacks.com reports. Svb Leerink also issued estimates for Fulcrum Therapeutics’ Q2 2019 earnings at ($0.05) EPS, Q3 2019 earnings at ($0.26) EPS, Q4 2019 earnings at ($0.25) EPS, FY2019 earnings at ($0.75) EPS, FY2020 earnings at ($2.48) EPS, FY2021 earnings at ($3.24) EPS, FY2022 earnings at ($3.02) EPS and FY2023 earnings at ($1.15) EPS.

Several other research analysts have also issued reports on FULC. Morgan Stanley started coverage on shares of Fulcrum Therapeutics in a research note on Monday. They issued an “overweight” rating and a $29.00 price target for the company. Bank of America started coverage on shares of Fulcrum Therapeutics in a research note on Monday. They issued a “buy” rating and a $19.00 price target for the company.

Shares of Fulcrum Therapeutics stock opened at $10.20 on Monday. Fulcrum Therapeutics has a 1 year low of $10.08 and a 1 year high of $15.94.

In other news, major shareholder 6 Dimensions Capital, L.P. acquired 118,750 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The shares were bought at an average cost of $16.00 per share, with a total value of $1,900,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Mark J. Levin acquired 81,250 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $1,300,000.00. The disclosure for this purchase can be found here.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia.

See Also: Market Capitalization

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.